Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Rosenberg Website

Steven A. Rosenberg, M.D., Ph.D.

Selected Publications

1)  Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA.
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Science. 344: 641-5, 2014.
[Journal]
2)  Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA.
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors.
J. Clin. Invest. 124: 2246-59, 2014.
[Journal]
3)  Liu B, Zhong S, Malecek K, Johnson LA, Rosenberg SA, Zhu C, Krogsgaard M.
2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system.
Eur. J. Immunol. 44: 239-50, 2014.
[Journal]
4)  Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Scolyer RA, Mann GJ, Thompson JF, Hayward NK, Samuels Y.
A highly recurrent RPS27 5"UTR mutation in melanoma.
Oncotarget. 5: 2912-7, 2014.
[Journal]
5)  Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA.
A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer.
Hum. Gene Ther. [Epub ahead of print], 2014.
[Journal]
6)  Rosati SF, Parkhurst MR, Hong Y, Zheng Z, Feldman SA, Rao M, Abate-Daga D, Beard RE, Xu H, Black MA, Robbins PF, Schrump DA, Rosenberg SA, Morgan RA.
A novel murine T-cell receptor targeting NY-ESO-1.
J. Immunother. 37: 135-46, 2014.
[Journal]
7)  Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg SA, Morgan RA.
Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
PLoS ONE. 9: e93321, 2014.
[Journal]
8)  Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U.
Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial.
Ann. Surg. Oncol. [Epub ahead of print], 2014.
[Journal]
9)  Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF.
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
Clin. Cancer Res. 20: 3401-10, 2014.
[Journal]
10)  Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, Herndon JE, Kuan CT, Morgan RA, Rosenberg SA, Johnson LA.
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
Clin. Cancer Res. 20: 972-84, 2014.
[Journal]
11)  Hinrichs CS, Rosenberg SA.
Exploiting the curative potential of adoptive T-cell therapy for cancer.
Immunol. Rev. 257: 56-71, 2014.
[Journal]
12)  Aung PP, Liu YC, Ballester LY, Robbins PF, Rosenberg SA, Lee CC.
Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma.
Hum. Pathol. 45: 259-67, 2014.
[Journal]
13)  Rosenberg SA.
Finding suitable targets is the major obstacle to cancer gene therapy.
Cancer Gene Ther. 21: 45-7, 2014.
[Journal]
14)  Bartlett EK, Fetsch PA, Filie AC, Abati A, Steinberg SM, Wunderlich JR, White DE, Stephens DJ, Marincola FM, Rosenberg SA, Kammula US.
Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration.
Clin. Cancer Res. [Epub ahead of print], 2014.
[Journal]
15)  Rosenberg SA.
IL-2: The First Effective Immunotherapy for Human Cancer.
J. Immunol. 192: 5451-8, 2014.
[Journal]
16)  Liu Q, Tomei S, Ascierto ML, De Giorgi V, Bedognetti D, Dai C, Uccellini L, Spivey T, Pos Z, Thomas J, Reinboth J, Murtas D, Zhang Q, Chouchane L, Weiss GR, Slingluff CL, Lee PP, Rosenberg SA, Alter H, Yao K, Wang E, Marincola FM.
Melanoma NOS1 expression promotes dysfunctional IFN signaling.
J. Clin. Invest. 124: 2147-59, 2014.
[Journal]
17)  Yang JC, Sherry RM, Rosenberg SA.
Melanoma: Why is sentinel lymph node biopsy "standard of care" for melanoma?.
Nat Rev Clin Oncol. 11: 245-6, 2014.
[Journal]
18)  Prickett TD, Zerlanko B, Gartner JJ, Parker SC, Dutton-Regester K, Lin JC, Teer JK, Wei X, Jiang J, Chen G, Davies MA, Gershenwald JE, Robinson W, Robinson S, Hayward NK, Rosenberg SA, Margulies EH, Samuels Y.
Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin.
J. Invest. Dermatol. 134: 452-60, 2014.
[Journal]
19)  Tseng J, Citrin DE, Waldman M, White DE, Rosenberg SA, Yang JC.
Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation.
Cancer. 120: 1426-32, 2014.
[Journal]
20)  Turcotte S, Gros A, Tran E, Lee CC, Wunderlich JR, Robbins PF, Rosenberg SA.
Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.
Clin. Cancer Res. 20: 331-43, 2014.
[Journal]
21)  Phan GQ, Rosenberg SA.
Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.
Cancer Control. 20: 289-97, 2013.
[Journal]
22)  Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
J. Immunother. 36: 133-51, 2013.
[Journal]
23)  Casati A, Varghaei-Nahvi A, Feldman SA, Assenmacher M, Rosenberg SA, Dudley ME, Scheffold A.
Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients.
Cancer Immunol. Immunother. 62: 1563-73, 2013.
[Journal]
24)  Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA, Restifo NP.
Collapse of the Tumor Stroma is Triggered by IL-12 Induction of Fas.
Mol. Ther. 21: 1369-77, 2013.
[Journal]
25)  Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, Ascierto ML, De Giorgi V, Liu Q, Delogu LG, Sommariva M, Sertoli MR, Simon R, Wang E, Rosenberg SA, Marincola FM.
CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.
Br. J. Cancer. 109: 2412-23, 2013.
[Journal]
26)  Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Blood. 122: 4129-39, 2013.
[Journal]
27)  Malecek K, Zhong S, McGary K, Yu C, Huang K, Johnson LA, Rosenberg SA, Krogsgaard M.
Engineering improved T cell receptors using an alanine-scan guided T cell display selection system.
J. Immunol. Methods. 392: 1-11, 2013.
[Journal]
28)  Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, Morgan RA.
Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes.
Blood. 122: 1399-410, 2013.
[Journal]
29)  Beard RE, Abate-Daga D, Rosati SF, Zheng Z, Wunderlich JR, Rosenberg SA, Morgan RA.
Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy.
Clin. Cancer Res. 19: 4941-50, 2013.
[Journal]
30)  Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, Rosenberg SA.
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia.
J. Exp. Med. 210: 1125-35, 2013.
[Journal]
31)  Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA.
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.
Nat. Med. 19: 747-52, 2013.
[Journal]
32)  Yang S, Ji Y, Gattinoni L, Zhang L, Yu Z, Restifo NP, Rosenberg SA, Morgan RA.
Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.
Cancer Immunol. Immunother. 62: 727-36, 2013.
[Journal]
33)  Lu YC, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA, Robbins PF.
Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression.
J. Immunol. 190: 6034-42, 2013.
[Journal]
34)  Turcotte S, Gros A, Hogan K, Tran E, Hinrichs CS, Wunderlich JR, Dudley ME, Rosenberg SA.
Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.
J. Immunol. 191: 2217-25, 2013.
[Journal]
35)  Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA.
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
J. Clin. Oncol. 31: 2152-9, 2013.
[Journal]
36)  Chinnasamy D, Tran E, Yu Z, Morgan RA, Restifo NP, Rosenberg SA.
Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.
Cancer Res. 73: 3371-80, 2013.
[Journal]
37)  Chen S, Li Y, Depontieu FR, McMiller TL, English AM, Shabanowitz J, Kos F, Sidney J, Sette A, Rosenberg SA, Hunt DF, Mariuzza RA, Topalian SL.
Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity.
J. Immunol. 191: 5097-106, 2013.
[Journal]
38)  Zhong S, Malecek K, Johnson LA, Yu Z, Vega-Saenz de Miera E, Darvishian F, McGary K, Huang K, Boyer J, Corse E, Shao Y, Rosenberg SA, Restifo NP, Osman I, Krogsgaard M.
T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy.
Proc. Natl. Acad. Sci. U.S.A. 110: 6973-8, 2013.
[Journal]
39)  Kochenderfer JN, Rosenberg SA.
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Nat Rev Clin Oncol. 10: 267-76, 2013.
[Journal]
40)  Gartner JJ, Parker SC, Prickett TD, Dutton-Regester K, Stitzel ML, Lin JC, Davis S, Simhadri VL, Jha S, Katagiri N, Gotea V, Teer JK, Wei X, Morken MA, Bhanot UK, Chen G, Elnitski LL, Davies MA, Gershenwald JE, Carter H, Karchin R, Robinson W, Robinson S, Rosenberg SA, Collins FS, Parmigiani G, Komar AA, Kimchi-Sarfaty C, Hayward NK, Margulies EH, Samuels Y.
Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma.
Proc. Natl. Acad. Sci. U.S.A. 110: 13481-6, 2013.
[Journal]
41)  Yang S, Karne NK, Goff SL, Black MA, Xu H, Bischof D, Cornetta K, Rosenberg SA, Morgan RA, Feldman SA.
A Simple and Effective Method to Generate Lentiviral Vectors for ex Vivo Gene Delivery to Mature Human Peripheral Blood Lymphocytes.
Hum Gene Ther Methods. 23: 73-83, 2012.
[Journal]
42)  Restifo NP, Dudley ME, Rosenberg SA.
Adoptive immunotherapy for cancer: harnessing the T cell response.
Nat. Rev. Immunol. 12: 269-81, 2012.
[Journal]
43)  Seaman BJ, Guardiani EA, Brewer CC, Zalewski CK, King KA, Rudy S, Van Waes C, Morgan RA, Dudley ME, Yang JC, Rosenberg SA, Kim HJ.
Audiovestibular Dysfunction Associated with Adoptive Cell Immunotherapy for Melanoma.
Otolaryngol Head Neck Surg. 147: 744-9, 2012.
[Journal]
44)  Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Blood. 119: 2709-20, 2012.
[Journal]
45)  Zhu S, Van den Eynde BJ, Coulie PG, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.
Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.
J. Immunother. 35: 680-8, 2012.
[Journal]
46)  Bergamaschi C, Bear J, Rosati M, Beach RK, Alicea C, Sowder R, Chertova E, Rosenberg SA, Felber BK, Pavlakis GN.
Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum.
Blood. 120: e1-8, 2012.
[Journal]
47)  Somerville RP, Devillier L, Parkhurst MR, Rosenberg SA, Dudley ME.
Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE(R) bioreactor.
J Transl Med. 10: 69, 2012.
[Journal]
48)  Gartner JJ, Davis S, Wei X, Lin JC, Trivedi NS, Teer JK, Meltzer PS, Rosenberg SA, Samuels Y.
Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma.
BMC Genomics. 13: 505, 2012.
[Journal]
49)  Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ.
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
Clin. Cancer Res. 18: 2039-47, 2012.
[Journal]
50)  Zhang L, Feldman SA, Zheng Z, Chinnasamy N, Xu H, Nahvi AV, Dudley ME, Rosenberg SA, Morgan RA.
Evaluation of gamma-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application.
J. Immunother. 35: 430-9, 2012.
[Journal]
51)  Zhang L, Yu Z, Muranski P, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA.
Inhibition of TGF-ß signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
Gene Ther. [Epub ahead of print], 2012.
[Journal]
52)  Uccellini L, De Giorgi V, Zhao Y, Tumaini B, Erdenebileg N, Dudley ME, Tomei S, Bedognetti D, Ascierto ML, Liu Q, Simon R, Kottyan L, Kaufman KM, Harley JB, Wang E, Rosenberg SA, Marincola FM.
IRF5 gene polymorphisms in melanoma.
J Transl Med. 10: 170, 2012.
[Journal]
53)  Yao X, Ahmadzadeh M, Lu Y, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF.
Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.
Blood. 119: 5688-96, 2012.
[Journal]
54)  Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, Rosenberg SA.
Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice.
Clin. Cancer Res. 18: 1672-83, 2012.
[Journal]
55)  Alvarez-Downing MM, Inchauste SM, Dudley ME, White DE, Wunderlich JR, Rosenberg SA, Kammula US.
Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
World J Surg Oncol. 10: 113, 2012.
[Journal]
56)  Parker SC, Gartner J, Cardenas-Navia I, Wei X, Ozel Abaan H, Ajay SS, Hansen NF, Song L, Bhanot UK, Killian JK, Gindin Y, Walker RL, Meltzer PS, Mullikin JC, Furey TS, Crawford GE, Rosenberg SA, Samuels Y, Margulies EH.
Mutational signatures of de-differentiation in functional non-coding regions of melanoma genomes.
PLoS Genet. 8: e1002871, 2012.
[Journal]
57)  Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA.
Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma.
Clin. Cancer Res. 18: 5212-23, 2012.
[Journal]
58)  Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM, Miller JS, Mostoslavsky G, Powell DJ, Rao M, Restifo NP, Rosenberg SA, O'Shea J, Melief CJ.
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.
J Transl Med. 10: 48, 2012.
[Journal]
59)  Lai JP, Robbins PF, Raffeld M, Aung PP, Tsokos M, Rosenberg SA, Miettinen MM, Lee CC.
NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
Mod. Pathol. 25: 854-8, 2012.
[Journal]
60)  Rosenberg SA.
Raising the bar: the curative potential of human cancer immunotherapy.
Sci Transl Med. 4: 127ps8, 2012.
[Journal]
61)  Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA.
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
Hum. Gene Ther. 23: 1043-53, 2012.
[Journal]
62)  Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, Heslop HE, Dotti G.
Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?.
Mol. Ther. 20: 246-9, 2012.
[Journal]
63)  Jin J, Sabatino M, Somerville R, Wilson JR, Dudley ME, Stroncek DF, Rosenberg SA.
Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment.
J. Immunother. 35: 283-92, 2012.
[Journal]
64)  June C, Rosenberg SA, Sadelain M, Weber JS.
T-cell therapy at the threshold.
Nat. Biotechnol. 30: 611-4, 2012.
[Journal]
65)  Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T, Dudley ME, Restifo NP, Rosenberg SA, Kammula US.
The stoichiometric production of IL-2 and IFN-? mRNA defines memory T cells that can self-renew after adoptive transfer in humans.
Sci Transl Med. 4: 149ra120, 2012.
[Journal]
66)  Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, van Rooij N, Linnemann C, van Buuren MM, Urbanus JH, Beltman JB, Thor Straten P, Li YF, Robbins PF, Besser MJ, Schachter J, Kenter GG, Dudley ME, Rosenberg SA, Haanen JB, Hadrup SR, Schumacher TN.
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.
Oncoimmunology. 1: 409-418, 2012.
[Journal]
67)  Friedman KM, Prieto PA, Devillier LE, Gross CA, Yang JC, Wunderlich JR, Rosenberg SA, Dudley ME.
Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes.
J. Immunother. 35: 400-8, 2012.
[Journal]
68)  Devita VT, Rosenberg SA.
Two Hundred Years of Cancer Research.
New Engl J Med. 366: 2207-14, 2012.
[Journal]
69)  Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA.
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
J. Immunol. 186: 685-96, 2011.
[Journal]
70)  Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA.
Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.
Clin Cancer Res. 17: 6287-97, 2011.
[Journal]
71)  Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, Hanada K, Yang JC, Rosenberg SA, Van den Eynde BJ.
An antigenic peptide produced by reverse splicing and double asparagine deamidation.
Proc. Natl. Acad. Sci. U.S.A. 108: E323-31, 2011.
[Journal]
72)  Wei X, Moncada-Pazos A, Cal S, Soria-Valles C, Gartner J, Rudloff U, Lin JC, Rosenberg SA, López-Otín C, Samuels Y.
Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma.
Hum. Mutat. 32: E2148-75, 2011.
[Journal]
73)  Langan RC, Prieto PA, Sherry RM, Zlott D, Wunderlich J, Csako G, Costello R, White DE, Rosenberg SA, Yang JC.
Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy.
J. Immunother. 34: 397-402, 2011.
[Journal]
74)  Friedman KM, Devillier LE, Feldman SA, Rosenberg SA, Dudley ME.
Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement.
J. Immunother. 34: 651-61, 2011.
[Journal]
75)  Rosenberg SA.
Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know.
Nat Rev Clin Oncol. 8: 577-85, 2011.
[Journal]
76)  Kochenderfer JN, Rosenberg SA.
Chimeric antigen receptor-modified T cells in CLL.
N. Engl. J. Med. 365: 1937-8; author reply 1938, 2011.
[Journal]
77)  Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J, Cooper LJ, Corrigan-Curay J, Strome SE.
Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010.
Cancer Res. 71: 3175-81, 2011.
[Journal]
78)  Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE, Rosenberg SA, Restifo NP.
Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice.
Clin. Cancer Res. 17: 5343-52, 2011.
[Journal]
79)  Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME.
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy.
Clin Cancer Res. 17: 4550-7, 2011.
[Journal]
80)  Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y.
Exome sequencing identifies GRIN2A as frequently mutated in melanoma.
Nat. Genet. 43: 442-6, 2011.
[Journal]
81)  Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, Davies MA, Gershenwald JE, Stemke-Hale K, Rosenberg SA, Margulies EH, Samuels Y.
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.
Nat. Genet. 43: 1119-26, 2011.
[Journal]
82)  Kerkar SP, Sanchez-Perez L, Yang S, Borman ZA, Muranski P, Ji Y, Chinnasamy D, Kaiser AD, Hinrichs CS, Klebanoff CA, Scott CD, Gattinoni L, Morgan RA, Rosenberg SA, Restifo NP.
Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
J. Immunother. 34: 343-52, 2011.
[Journal]
83)  Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P.
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
N. Engl. J. Med. 364: 2119-27, 2011.
[Journal]
84)  Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, Rosenberg SA, Restifo NP.
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.
Blood. 117: 808-14, 2011.
[Journal]
85)  Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM, Trinchieri G, Rosenberg SA, Restifo NP.
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.
J. Clin. Invest. 121: 4746-57, 2011.
[Journal]
86)  Turcotte S, Rosenberg SA.
Immunotherapy for metastatic solid cancers.
Adv Surg. 45: 341-60, 2011.
[Journal]
87)  Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA.
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.
Mol. Ther. 19: 751-9, 2011.
[Journal]
88)  Yang S, Gattinoni L, Luca G, Liu F, Ji Y, Yu Z, Restifo NP, Rosenberg SA, Morgan RA.
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.
Cancer Immunol. Immunother. 60: 739-49, 2011.
[Journal]
89)  Huang J, Wang QJ, Yang S, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.
Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro.
J. Immunother. 34: 327-35, 2011.
[Journal]
90)  Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim JS, Waldman T.
Mutational inactivation of STAG2 causes aneuploidy in human cancer.
Science. 333: 1039-43, 2011.
[Journal]
91)  Rosenberg SA, Kochenderfer JN.
Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers.
Mol. Ther. 19: 1928-30, 2011.
[Journal]
92)  Feldman SA, Goff SL, Xu H, Black MA, Kochenderfer JN, Johnson LA, Yang JC, Wang Q, Parkhurst MR, Cross S, Morgan RA, Cornetta K, Rosenberg SA.
Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a.
Hum. Gene Ther. 22: 107-15, 2011.
[Journal]
93)  Lonser RR, Song DK, Klapper J, Hagan M, Auh S, Kerr PB, Citrin DE, Heiss JD, Camphausen K, Rosenberg SA.
Surgical management of melanoma brain metastases in patients treated with immunotherapy.
J Neurosurg. 115: 30-6, 2011.
[Journal]
94)  Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA.
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Mol. Ther. 19: 620-6, 2011.
[Journal]
95)  Yang S, Liu F, Wang QJ, Rosenberg SA, Morgan RA.
The Shedding of CD62L (L-Selectin) Regulates the Acquisition of Lytic Activity in Human Tumor Reactive T Lymphocytes.
PLoS ONE. 6: e22560, 2011.
[Journal]
96)  Park TS, Rosenberg SA, Morgan RA.
Treating cancer with genetically engineered T cells.
Trends Biotech. 29: 550-7, 2011.
[Journal]
97)  Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
J. Clin. Oncol. 29: 917-24, 2011.
[Journal]
98)  Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA.
A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas.
Cancer Res. 70: 3027-33, 2010.
[Journal]
99)  Yang S, Dudley ME, Rosenberg SA, Morgan RA.
A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors.
J. Immunother. 33: 648-58, 2010.
[Journal]
100)  Morgan RA, Dudley ME, Rosenberg SA.
Adoptive cell therapy: genetic modification to redirect effector cell specificity.
Cancer J. 16: 336-41, 2010.
[Journal]
101)  Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA.
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
Blood. 116: 3875-86, 2010.
[Journal]
102)  Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA.
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
Cancer Res. 70: 6171-80, 2010.
[Journal]
103)  Frankel TL, Burns WR, Peng PD, Yu Z, Chinnasamy D, Wargo JA, Zheng Z, Restifo NP, Rosenberg SA, Morgan RA.
Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
J. Immunol. 184: 5988-98, 2010.
[Journal]
104)  Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA.
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
Mol. Ther. 18: 843-51, 2010.
[Journal]
105)  Davis JL, Theoret MR, Zheng Z, Lamers CH, Rosenberg SA, Morgan RA.
Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials.
Clin. Cancer Res. 16: 5852-61, 2010.
[Journal]
106)  Rosenberg SA, Yang JC, Kammula US, Hughes MS, Restifo NP, Schwarz SL, Morton KE, Laurencot CM, Sherry RM.
Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.
J. Immunother. 33: 626-9, 2010.
[Journal]
107)  Goff SL, Johnson LA, Black MA, Xu H, Zheng Z, Cohen CJ, Morgan RA, Rosenberg SA, Feldman SA.
Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion.
Cancer Immunol. Immunother. 59: 1551-60, 2010.
[Journal]
108)  Prieto PA, Durflinger KH, Wunderlich JR, Rosenberg SA, Dudley ME.
Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.
J. Immunother. 33: 547-56, 2010.
[Journal]
109)  Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA.
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.
J. Clin. Invest. 120: 3953-68, 2010.
[Journal]
110)  Frankel TL, Burns W, Riley J, Morgan RA, Davis JL, Hanada K, Quezado M, Rosenberg SA, Royal RE.
Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines.
Cancer Immunol. Immunother. 59: 1757-69, 2010.
[Journal]
111)  Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD, McLendon RE, Rosenberg SA, Samuels Y, Yan H.
IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain.
Biochem. Biophys. Res. Commun. 398: 585-7, 2010.
[Journal]
112)  Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP.
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.
J. Immunother. 33: 1-7, 2010.
[Journal]
113)  Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I.
Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy.
Ann. Surg. Oncol. 17: 163-70, 2010.
[Journal]
114)  Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B.
MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.
Clin. Immunol. 136: 338-47, 2010.
[Journal]
115)  Wei X, Prickett TD, Viloria CG, Molinolo A, Lin JC, Cardenas-Navia I, Cruz P, Rosenberg SA, Davies MA, Gershenwald JE, López-Otín C, Samuels Y.
Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma.
Mol. Cancer Res. 8: 1513-25, 2010.
[Journal]
116)  Cárdenas-Navia LI, Cruz P, Lin JC, Rosenberg SA, Samuels Y.
Novel somatic mutations in heterotrimeric G proteins in melanoma.
Cancer Biol Ther. 10: 33-7, 2010.
[Journal]
117)  Rosenberg SA.
Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells.
Mol. Ther. 18: 1744-5, 2010.
[Journal]
118)  Davis JL, Ripley RT, Frankel TL, Maric I, Lozier JN, Rosenberg SA.
Paraneoplastic granulocytosis in metastatic melanoma.
Melanoma Res. 20: 326-9, 2010.
[Journal]
119)  Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA.
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.
J. Immunother. 33: 828-33, 2010.
[Journal]
120)  Kalbasi A, Shrimali RK, Chinnasamy D, Rosenberg SA.
Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.
J. Immunother. 33: 672-83, 2010.
[Journal]
121)  Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC.
Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.
J. Immunother. 33: 956-64, 2010.
[Journal]
122)  Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, Sherry RM.
Successful treatment of melanoma brain metastases with adoptive cell therapy.
Clin. Cancer Res. 16: 4892-8, 2010.
[Journal]
123)  Klapper JA, Davis JL, Ripley RT, Smith FO, Nguyen DM, Kwong KF, Mercedes L, Kemp CD, Mathur A, White DE, Dudley ME, Wunderlich JR, Rosenberg SA, Schrump DS.
Thoracic metastasectomy for adoptive immunotherapy of melanoma: A single-institution experience.
J Thorac Cardiovasc Surg. 140: 1276-82, 2010.
[Journal]
124)  Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, White D, Rosenberg SA, Dudley ME, Yang JC.
Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.
J. Immunother. 33: 840-7, 2010.
[Journal]
125)  Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L, Morgan RA, Gattinoni L, Rosenberg SA, Trinchieri G, Restifo NP.
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.
Cancer Res. 70: 6725-34, 2010.
[Journal]
126)  Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA.
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.
J. Immunol. 183: 5563-74, 2009.
[Journal]
127)  Rosenberg SA, Dudley ME.
Adoptive cell therapy for the treatment of patients with metastatic melanoma.
Curr. Opin. Immunol. 21: 233-40, 2009.
[Journal]
128)  Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP.
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.
Proc. Natl. Acad. Sci. U.S.A. 106: 17469-74, 2009.
[Journal]
129)  Palavalli LH, Prickett TD, Wunderlich JR, Wei X, Burrell AS, Porter-Gill P, Davis S, Wang C, Cronin JC, Agrawal NS, Lin JC, Westbroek W, Hoogstraten-Miller S, Molinolo AA, Fetsch P, Filie AC, O'Connell MP, Banister CE, Howard JD, Buckhaults P, Weeraratna AT, Brody LC, Rosenberg SA, Samuels Y.
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma.
Nat. Genet. 41: 518-20, 2009.
[Journal]
130)  Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y.
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Nat. Genet. 41: 1127-32, 2009.
[Journal]
131)  Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, Rosenberg SA.
Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.
Clin. Cancer Res. 15: 169-80, 2009.
[Journal]
132)  Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA.
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
J. Immunother. 32: 689-702, 2009.
[Journal]
133)  Peng PD, Cohen CJ, Yang S, Hsu C, Jones S, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA.
Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.
Gene Ther. 16: 1042-1049, 2009.
[Journal]
134)  Cronin JC, Wunderlich J, Loftus SK, Prickett TD, Wei X, Ridd K, Vemula S, Burrell AS, Agrawal NS, Lin JC, Banister CE, Buckhaults P, Rosenberg SA, Bastian BC, Pavan WJ, Samuels Y.
Frequent mutations in the MITF pathway in melanoma.
Pigment Cell Melanoma Res. 22: 435-44, 2009.
[Journal]
135)  Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CR, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, Vanwaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA.
Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Blood. 114: 535-546, 2009.
[Journal]
136)  Smith FO, Klapper JA, Wunderlich JR, Rosenberg SA, Dudley ME.
Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma.
J. Immunother. 32: 870-4, 2009.
[Journal]
137)  Burns WR, Zheng Z, Rosenberg SA, Morgan RA.
Lack of specific {gamma}-retroviral vector LTR promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.
Blood. 114: 2888-99, 2009.
[Journal]
138)  Jones S, Peng PD, Yang S, Hsu C, Cohen CJ, Zhao Y, Abad J, Zheng Z, Rosenberg SA, Morgan RA.
Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Hum. Gene Ther. 20: 630-40, 2009.
[Journal]
139)  Goff SL, Robbins PF, El-Gamil M, Rosenberg SA.
No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma.
J. Immunother. 32: 884-5, 2009.
[Journal]
140)  Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, Li Z, Bishop RJ, Wong WT, Sherry RM, Yang JC, Dudley ME, Restifo NP, Rosenberg SA, Nussenblatt RB.
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
Ophthalmology. 116: 981-989.e1, 2009.
[Journal]
141)  Klapper JA, Thomasian AA, Smith DM, Gorgas GC, Wunderlich JR, Smith FO, Hampson BS, Rosenberg SA, Dudley ME.
Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy.
J. Immunol. Methods. 345: 90-9, 2009.
[Journal]
142)  Kerkar SP, Kemp CD, Duffy A, Kammula US, Schrump DS, Kwong KF, Quezado M, Goldspiel BR, Venkatesan A, Berger A, Walker M, Toomey MA, Steinberg SM, Giaccone G, Rosenberg SA, Avital I.
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.
Trials. 10: 121, 2009.
[Journal]
143)  Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA.
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
Blood. 114: 1537-1544, 2009.
[Journal]
144)  Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, Downey S, Zheng Z, Shelton TE, Matsuda K, Robbins PF, Morgan RA, Rosenberg SA.
Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.
Hum. Gene Ther. 19: 496-510, 2008.
[Journal]
145)  Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA.
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
J. Clin. Oncol. 26: 5233-9, 2008.
[Journal]
146)  Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME.
Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
Nat. Rev. Cancer. 8: 299-308, 2008.
[Journal]
147)  Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA, Restifo NP.
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
Blood. 112: 4746-54, 2008.
[Journal]
148)  Rosenberg SA, Dudley ME, Restifo NP.
Cancer immunotherapy.
N. Engl. J. Med. 359: 1072, 2008.
[Journal]
149)  Yang S, Rosenberg SA, Morgan RA.
Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells.
J. Immunother. 31: 830-9, 2008.
[Journal]
150)  Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, Yu Z, Zheng Z, Jones S, Restifo NP, Rosenberg SA, Morgan RA.
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.
Gene Ther. 15: 1411-23, 2008.
[Journal]
151)  Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP.
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.
Proc. Natl. Acad. Sci. U.S.A. 105: 8061-6, 2008.
[Journal]
152)  Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell DJ, Wunderlich JR, Merino MJ, Rosenberg SA.
FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.
Blood. 112: 4953-60, 2008.
[Journal]
153)  Klapper J, Downey S, Smith F, Yang J, Hughes M, Kammula U, Sherry R, Royal R, Steinberg S, Rosenberg S.
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma.
Cancer. 113: 293-301, 2008.
[Journal]
154)  Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP.
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.
Blood. 111: 5326-33, 2008.
[Journal]
155)  Breunis WB, Tarazona-Santos E, Chen R, Kiley M, Rosenberg SA, Chanock SJ.
Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.
J. Immunother. 31: 586-90, 2008.
[Journal]
156)  Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME.
Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.
J. Immunother. 31: 742-51, 2008.
[Journal]
157)  Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Rosenberg SA, Ressom H, Jean W, Bigner D, Yan H, Samuels Y, Waldman T.
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
Cancer Res. 68: 10300-6, 2008.
[Journal]
158)  Rosenberg SA.
Overcoming obstacles to the effective immunotherapy of human cancer.
Proc. Natl. Acad. Sci. U.S.A. 105: 12643-4, 2008.
[Journal]
159)  Powell DJ, Attia P, Ghetie V, Schindler J, Vitetta ES, Rosenberg SA.
Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.
J. Immunother. 31: 189-98, 2008.
[Journal]
160)  Wargo JA, Robbins PF, Li Y, Zhao Y, El-Gamil M, Caragacianu D, Zheng Z, Hong JA, Downey S, Schrump DS, Rosenberg SA, Morgan RA.
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
Cancer Immunol. Immunother. 2008.
[Journal]
161)  Theoret MR, Cohen CJ, Nahvi AV, Ngo LT, Suri KB, Powell DJ, Dudley ME, Morgan RA, Rosenberg SA.
Relationship of p53 Overexpression on Cancers and Recognition by anti-p53 TCR Transduced T cells.
Hum. Gene Ther. 2008.
[Journal]
162)  Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA.
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
J. Immunol. 180: 6116-31, 2008.
[Journal]
163)  Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA.
T-cell receptor gene therapy of established tumors in a murine melanoma model.
J. Immunother. 31: 1-6, 2008.
[Journal]
164)  Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA.
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.
Clin. Cancer Res. 14: 5610-8, 2008.
[Journal]
165)  Rosenberg SA.
Why perform sentinel-lymph-node biopsy in patients with melanoma?.
Nat Clin Pract Oncol. 5: 1, 2008.
[Journal]
166)  Powell DJ, Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, White DE, Mavroukakis S, Kreitman RJ, Rosenberg SA, Pastan I.
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
J. Immunol. 179: 4919-28, 2007.
[Journal]
167)  Dudley ME, Rosenberg SA.
Adoptive cell transfer therapy.
Semin. Oncol. 34: 524-31, 2007.
[Journal]
168)  Hsu C, Jones SA, Cohen CJ, Zheng Z, Kerstann K, Zhou J, Robbins PF, Peng PD, Shen X, Gomes TJ, Dunbar CE, Munroe DJ, Stewart C, Cornetta K, Wangsa D, Ried T, Rosenberg SA, Morgan RA.
Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene.
Blood. 109: 5168-77, 2007.
[Journal]
169)  Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA.
Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.
Cancer Res. 67: 3898-903, 2007.
[Journal]
170)  Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L, Restifo NP, Rosenberg SA, Morgan RA.
Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling.
Cancer Res. 67: 2425-9, 2007.
[Journal]
171)  Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, Rosenberg SA, Restifo NP.
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
J. Clin. Invest. 117: 492-501, 2007.
[Journal]
172)  Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, Yu LY, Li Y, Molloy PE, Dunn SM, Jakobsen BK, Rosenberg SA, Morgan RA.
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines.
J. Immunol. 179: 5845-54, 2007.
[Journal]
173)  Ahmadzadeh M, Antony PA, Rosenberg SA.
IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells.
J. Immunother. 30: 294-302, 2007.
[Journal]
174)  Powell DJ, de Vries CR, Allen T, Ahmadzadeh M, Rosenberg SA.
Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy.
J. Immunother. 30: 438-47, 2007.
[Journal]
175)  Rosenberg SA.
Interleukin 2 for patients with renal cancer.
Nat. Clin. Pract. Oncol. 4: 497, 2007.
[Journal]
176)  Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA.
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.
J. Immunother. 30: 825-30, 2007.
[Journal]
177)  Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP.
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8 T cells via TLR4 signaling.
J. Clin. Invest. 117: 2197-204, 2007.
[Journal]
178)  Shen X, Zhou J, Hathcock KS, Robbins P, Powell DJ, Rosenberg SA, Hodes RJ.
Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length.
J. Immunother. 30: 123-9, 2007.
[Journal]
179)  Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA.
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.
Clin. Cancer Res. 13: 6681-8, 2007.
[Journal]
180)  Smith FO, Goff SL, Klapper JA, Levy C, Allen T, Mavroukakis SA, Rosenberg SA.
Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody.
J. Immunother. 30: 130, 2007.
[Journal]
181)  Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, Antony PA, Gattinoni L, Rosenberg SA, Restifo NP.
Toll-like receptors in tumor immunotherapy.
Clin. Cancer Res. 13: 5280-9, 2007.
[Journal]
182)  Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P.
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
Clin. Cancer Res. 12: 6106-15, 2006.
[Journal]
183)  Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP.
Adoptive immunotherapy for cancer: building on success.
Nat. Rev. Immunol. 6: 383-93, 2006.
[Journal]
184)  Powell DJ, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA.
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
J. Immunol. 177: 6527-39, 2006.
[Journal]
185)  Rosenberg SA, Sherry RM, Morton KE, Yang JC, Topalian SL, Royal RE, Kammula US, Restifo NP, Hughes MS, Schwarz SL, Ngo LT, Mavroukakis SA, White DE.
Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.
J. Immunother. 29: 224-31, 2006.
[Journal]
186)  Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA.
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes.
Science. 314: 126-129, 2006.
[Journal]
187)  Gattinoni L, Ranganathan A, Surman DR, Palmer DC, Antony PA, Theoret MR, Heimann DM, Rosenberg SA, Restifo NP.
CTLA-4 dysregulation of self/tumor-reactive CD8+ T cell function is CD4+ T cell-dependent.
Blood. 108: 3818-23, 2006.
[Journal]
188)  Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA.
Enhanced Antitumor Activity of Murine-Human Hybrid T-Cell Receptor (TCR) in Human Lymphocytes Is Associated with Improved Pairing and TCR/CD3 Stability.
Cancer Res. 66: 8878-86, 2006.
[Journal]
189)  Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC.
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
J. Clin. Oncol. 24: 2283-9, 2006.
[Journal]
190)  Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, Rosenberg SA, Topalian SL.
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.
Clin. Cancer Res. 12: 2526-37, 2006.
[Journal]
191)  Johnson LA, Heemskerk B, Powell DJ, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA.
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.
J. Immunol. 177: 6548-59, 2006.
[Journal]
192)  Ahmadzadeh M, Rosenberg SA.
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
Blood. 107: 2409-14, 2006.
[Journal]
193)  Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M, Buffet R, Mackall CL, Gress RE.
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.
J. Immunother. 29: 313-9, 2006.
[Journal]
194)  Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP.
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?.
Nat. Clin. Pract. Oncol. 3: 668-81, 2006.
[Journal]
195)  Grover A, Kim GJ, Lizée G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P.
Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Clin. Cancer Res. 12: 5801-8, 2006.
[Journal]
196)  Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA.
Intrapatient Dose Escalation of Anti-CTLA-4 Antibody in Patients With Metastatic Melanoma.
J. Immunother. 29: 455-463, 2006.
[Journal]
197)  Romeo MJ, Wunderlich J, Ngo L, Rosenberg SA, Steinberg SM, Berman DM.
Measuring tissue-based biomarkers by immunochromatography coupled with reverse-phase lysate microarray.
Clin. Cancer Res. 12: 2463-7, 2006.
[Journal]
198)  Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.
Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.
J. Immunol. 176: 7726-35, 2006.
[Journal]
199)  Lotem M, Zhao Y, Riley J, Hwu P, Morgan RA, Rosenberg SA, Parkhurst MR.
Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors.
J. Immunother. 29: 616-27, 2006.
[Journal]
200)  Attia P, Powell DJ, Maker AV, Kreitman RJ, Pastan I, Rosenberg SA.
Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.
J. Immunother. 29: 208-14, 2006.
[Journal]
201)  Jaber SH, Cowen EW, Haworth LR, Booher SL, Berman DM, Rosenberg SA, Hwang ST.
Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
Arch. Dermatol. 142: 166-72, 2006.
[Journal]
202)  Zhao Y, Zheng Z, Khong HT, Rosenberg SA, Morgan RA.
Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into Primary Human CD4+ Lymphocytes.
J. Immunother. 29: 398-406, 2006.
[Journal]
203)  Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP.
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
J Clin Invest. 115: 1616-26, 2005.
[Journal]
204)  Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA.
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
J Clin Oncol. 23: 2346-57, 2005.
[Journal]
205)  Maker AV, Attia P, Rosenberg SA.
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
J. Immunol. 175: 7746-54, 2005.
[Journal]
206)  Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA.
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
J Clin Oncol. 23: 6043-53, 2005.
[Journal]
207)  Charo J, Finkelstein SE, Grewal N, Restifo NP, Robbins PF, Rosenberg SA.
Bcl-2 overexpression enhances tumor-specific T-cell survival.
Cancer Res. 65: 2001-8, 2005.
[Journal]
208)  Rosenberg SA.
Cancer immunotherapy comes of age.
Nat. Clin. Pract. Oncol. 2: 115, 2005.
[Journal]
209)  Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP.
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
J Immunol. 174: 2591-601, 2005.
[Journal]
210)  Rosenberg SA.
Cell transfer and other immunotherapeutic strategies.
Clin. Adv. Hematol. Oncol. 3: 28-9, 2005.
[Journal]
211)  Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP.
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
Proc. Natl. Acad. Sci. U.S.A. 102: 9571-6, 2005.
[Journal]
212)  Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM.
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
J. Immunother. 28: 593-8, 2005.
[Journal]
213)  Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP.
Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.
J. Immunother. 28: 517-24, 2005.
[Journal]
214)  Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA.
High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation.
Mol Ther. 13: 151-9, 2005.
[Journal]
215)  Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA.
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
J. Immunother. 28: 582-92, 2005.
[Journal]
216)  Powell DJ, Parker LL, Rosenberg SA.
Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples.
J Immunother. 28: 403-11, 2005.
[Journal]
217)  Aisner DL, Maker A, Rosenberg SA, Berman DM.
Loss of S100 antigenicity in metastatic melanoma.
Hum. Pathol. 36: 1016-9, 2005.
[Journal]
218)  Zhou J, Dudley ME, Rosenberg SA, Robbins PF.
Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
J Immunother. 28: 53-62, 2005.
[Journal]
219)  Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA.
Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.
J. Immunol. 174: 4415-23, 2005.
[Journal]
220)  Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, Morgan RA.
Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.
J. Immunol. 175: 7226-34, 2005.
[Journal]
221)  Cohen CJ, Zheng Z, Bray R, Zhao Y, Sherman LA, Rosenberg SA, Morgan RA.
Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.
J. Immunol. 175: 5799-808, 2005.
[Journal]
222)  Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP.
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
J. Exp. Med. 202: 907-12, 2005.
[Journal]
223)  Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF.
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.
J Immunother. 28: 258-67, 2005.
[Journal]
224)  Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF.
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.
J. Immunol. 175: 7046-52, 2005.
[Journal]
225)  Ahmadzadeh M, Rosenberg SA.
TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.
J Immunol. 174: 5215-23, 2005.
[Journal]
226)  Rosenberg SA.
The emergence of modern cancer immunotherapy.
Ann Surg Oncol. 12: 344-6, 2005.
[Journal]
227)  Hughes MS, Yu YY, Dudley ME, Zheng Z, Robbins PF, Li Y, Wunderlich J, Hawley RG, Moayeri M, Rosenberg SA, Morgan RA.
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.
Hum Gene Ther. 16: 457-72, 2005.
[Journal]
228)  Powell DJ, Dudley ME, Robbins PF, Rosenberg SA.
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.
Blood. 105: 241-50, 2005.
[Journal]
229)  Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, White DE, Steinberg SM.
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
J. Immunol. 175: 6169-76, 2005.
[Journal]
230)  Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA.
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Ann. Surg. Oncol. 12: 1005-16, 2005.
[Journal]
231)  Restifo NP, Rosenberg SA.
Use of standard criteria for assessment of cancer vaccines.
Lancet Oncol. 6: 3-4, 2005.
[Journal]
232)  Elaraj DM, White DE, Steinberg SM, Haworth L, Rosenberg SA, Yang JC.
A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma.
J. Immunother. 27: 259-64, 2004.
[Journal]
233)  Finkelstein SE, Carrasquillo JA, Hoffman JM, Galen B, Choyke P, White DE, Rosenberg SA, Sherry RM.
A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy.
Ann Surg Oncol. 11: 731-738, 2004.
[Journal]
234)  Finkelstein SE, Heimann DM, Klebanoff CA, Antony PA, Gattinoni L, Hinrichs CS, Hwang LN, Palmer DC, Spiess PJ, Surman DR, Wrzesiniski C, Yu Z, Rosenberg SA, Restifo NP.
Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer.
J Leukoc Biol. 76: 333-337, 2004.
[Journal]
235)  Rosenberg SA, Yang JC, Restifo NP.
Cancer immunotherapy: moving beyond current vaccines.
Nat. Med. 10: 909-15, 2004.
[Journal]
236)  Rosenberg SA, Dudley ME.
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.
Proc. Natl. Acad. Sci. U.S.A. 101 Suppl 2: 14639-45, 2004.
[Journal]
237)  Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ, Rosenberg SA.
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
J. Immunol. 173: 7125-30, 2004.
[Journal]
238)  Robinson MR, Chan C, Yang JC, Rubin BI, Gracia GJ, Sen HN, Csaky KG, Rosenberg SA.
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
J. Immunother. 27: 478-9, 2004.
[Journal]
239)  Rosenberg SA.
Development of effective immunotherapy for the treatment of patients with cancer.
J. Am. Coll. Surg. 198: 685-96, 2004.
[Journal]
240)  Khong HT, Wang QJ, Rosenberg SA.
Identification of Multiple Antigens Recognized by Tumor-Infiltrating Lymphocytes From a Single Patient: Tumor Escape by Antigen Loss and Loss of MHC Expression.
J Immunother. 27: 184-190, 2004.
[Journal]
241)  Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP.
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
Proc Natl Acad Sci U S A. 101: 1969-74, 2004.
[Journal]
242)  Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA.
Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
J. Immunother. 27: 472-7, 2004.
[Journal]
243)  Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA.
Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
Clin. Cancer Res. 10: 4688-98, 2004.
[Journal]
244)  Parkhurst MR, Riley JP, Robbins PF, Rosenberg SA.
Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.
J Immunother. 27: 79-91, 2004.
[Journal]
245)  Powell DJ, Rosenberg SA.
Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.
J Immunother. 27: 36-47, 2004.
[Journal]
246)  Zhou J, Dudley ME, Rosenberg SA, Robbins PF.
Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma.
J. Immunol. 173: 7622-9, 2004.
[Journal]
247)  Rosenberg SA.
Shedding light on immunotherapy for cancer.
N Engl J Med. 350: 1461-3, 2004.
[Journal]
248)  Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF.
T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.
J. Immunol. 172: 6057-64, 2004.
[Journal]
249)  Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA.
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
N Engl J Med. 349: 427-34, 2003.
[Journal]
250)  Dudley ME, Rosenberg SA.
Adoptive-cell-transfer therapy for the treatment of patients with cancer.
Nat Rev Cancer. 3: 666-75, 2003.
[Journal]
251)  Nagorsen D, Panelli M, Dudley ME, Finkelstein SE, Rosenberg SA, Marincola FM.
Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
Gene Ther. 10: 1754-65, 2003.
[Journal]
252)  Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Proc Natl Acad Sci. 100: 8372-8377, 2003.
[Journal]
253)  Javia LR, Rosenberg SA.
CD4+CD25+ Suppressor Lymphocytes in the Circulation of Patients Immunized Against Melanoma Antigens.
J Immunother. 26: 85-93, 2003.
[Journal]
254)  Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME.
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.
J Immunother. 26: 385-93, 2003.
[Journal]
255)  Heimann DM, Rosenberg SA.
Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma.
J Immunother. 26: 179-180, 2003.
[Journal]
256)  Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA.
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.
J Immunother. 26: 332-42, 2003.
[Journal]
257)  Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA.
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
J Immunol. 171: 3287-95, 2003.
[Journal]
258)  Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S.
Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
J Immunol. 170: 5317-25, 2003.
[Journal]
259)  Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.
Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.
Cancer Res. 63: 6735-43, 2003.
[Journal]
260)  Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
J Immunother. 26: 349-56, 2003.
[Journal]
261)  Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE.
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
Hum Gene Ther. 14: 709-714, 2003.
[Journal]
262)  Liu K, Rosenberg SA.
Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent.
J Immunother. 26: 190-201, 2003.
[Journal]
263)  Barrett JC, Bennett LM, Fleming LK, Linehan WM, Liotta LA, Rosenberg SA, Petricoin EF, Staudt LM, Thompson TE, Yang JC.
Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research.
Clin Adv Hematol Oncol. 1: 302-306, 2003.
[Journal]
264)  Touloukian CE, Leitner WW, Schnur RE, Robbins PF, Li Y, Southwood S, Sette A, Rosenberg SA, Restifo NP.
Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
J. Immunol. 170: 1579-85, 2003.
[Journal]
265)  Attia P, Phan GQ, Duray PH, Rosenberg SA.
Parathyroid hormone-related protein and hypercalcemia in patients with metastatic melanoma: case report and review.
Am. J. Clin. Oncol. 26: 42-5, 2003.
[Journal]
266)  Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA.
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
J Clin Oncol. 21: 3127-32, 2003.
[Journal]
267)  Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE.
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
Clin Cancer Res. 9: 2973-80, 2003.
[Journal]
268)  Riley JP, Rosenberg SA, Parkhurst MR.
Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
J Immunol Methods. 276: 103-19, 2003.
[Journal]
269)  Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP.
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
J Exp Med. 198: 569-80, 2003.
[Journal]
270)  Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA.
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.
J Immunother. 25: 243-51, 2002.
[Journal]
271)  Rosenberg SA, Spiess PJ, Kleiner DE.
Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium.
J Immunother. 25: 218-25, 2002.
[Journal]
272)  Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Science. 298: 850-4, 2002.
[Journal]
273)  McKee MD, Cecco SA, Niemela JE, Cormier J, Kim CJ, Steinberg SM, Rehak NN, Elin RJ, Rosenberg SA.
Effects of interleukin 2 therapy on lymphocyte magnesium levels.
J Lab Clin Med. 139: 5-12, 2002.
[Journal]
274)  Touloukian CE, Leitner WW, Robbins PF, Li YF, Kang X, Lapointe R, Hwu P, Rosenberg SA, Restifo NP.
Expression of a.
Cancer Res. 62: 5144-7, 2002.
[Journal]
275)  Seiter S, Monsurro V, Nielsen MB, Wang E, Provenzano M, Wunderlich JR, Rosenberg SA, Marincola FM.
Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
J Immunother. 25: 252-63, 2002.
[Journal]
276)  Monsurrò V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA, Marincola FM.
Functional heterogeneity of vaccine-induced CD8(+) T cells.
J Immunol. 168: 5933-42, 2002.
[Journal]
277)  Zeng G, Li Y, El-Gamil M, Sidney J, Sette A, Wang RF, Rosenberg SA, Robbins PF.
Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.
Cancer Res. 62: 3630-5, 2002.
[Journal]
278)  Rosenberg SA, Tong-On P, Li Y, Riley JP, El-Gamil M, Parkhurst MR, Robbins PF.
Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy.
J Immunol. 168: 2402-7, 2002.
[Journal]
279)  Thurber SE, Khong HT, Kammula US, Rosenberg SA.
Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction.
J Immunother. 25: 63-71, 2002.
[Journal]
280)  Marroquin CE, Westwood JA, Lapointe R, Mixon A, Wunderlich JR, Caron D, Rosenberg SA, Hwu P.
Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells.
J Immunother. 25: 278-88, 2002.
[Journal]
281)  Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M, Rosenberg SA.
Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
J Immunol. 169: 6036-47, 2002.
[Journal]
282)  Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA.
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
J Clin Oncol. 20: 142-52, 2002.
[Journal]
283)  Khong HT, Rosenberg SA.
Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy.
J Immunol. 168: 951-6, 2002.
[Journal]
284)  Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM.
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness.
Cancer Res. 62: 3581-6, 2002.
[Journal]
285)  Weinreich DM, Rosenberg SA.
Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2.
J Immunother. 25: 185-7, 2002.
[Journal]
286)  Guirguis LM, Yang JC, White DE, Steinberg SM, Liewehr DJ, Rosenberg SA, Schwartzentruber DJ.
Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.
J Immunother. 25: 82-7, 2002.
[Journal]
287)  Khong HT, Rosenberg SA.
The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy.
Cancer Res. 62: 3020-3, 2002.
[Journal]
288)  Ohnmacht GA, Phan GQ, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG, McIntyre LS, Goodwin RS, Muehlbauer PM, Morton KE, Rogers-Freezer LJ, Seipp CA, Rosenberg SA, Marincola FM.
A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2.
J Immunother. 24: 188-92, 2001.
[Journal]
289)  Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA.
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.
J Immunother. 24: 363-73, 2001.
[Journal]
290)  Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF.
CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
Proc Natl Acad Sci U S A. 98: 3964-9, 2001.
[Journal]
291)  Rosenberg SA.
Cellular therapy: an introduction.
Cancer J. 7 Suppl 2: S51-2, 2001.
[Journal]
292)  Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA.
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
J Clin Oncol. 19: 3477-82, 2001.
[Journal]
293)  Riley JP, Rosenberg SA, Parkhurst MR.
Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
J Immunother. 24: 212-20, 2001.
[Journal]
294)  Bownds S, Tong-On P, Rosenberg SA, Parkhurst M.
Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution.
J Immunother. 24: 1-9, 2001.
[Journal]
295)  Monsurrò V, Nielsen MB, Perez-Diez A, Dudley ME, Wang E, Rosenberg SA, Marincola FM.
Kinetics of TCR use in response to repeated epitope-specific immunization.
J Immunol. 166: 5817-25, 2001.
[Journal]
296)  Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM.
Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
J Urol. 166: 68-72, 2001.
[Journal]
297)  Mocellin S, Fetsch P, Abati A, Phan GQ, Wang E, Provenzano M, Stroncek D, Rosenberg SA, Marincola FM.
Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases.
J Immunother. 24: 447-58, 2001.
[Journal]
298)  Harada M, Li YF, El-Gamil M, Ohnmacht GA, Rosenberg SA, Robbins PF.
Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types.
J Immunother. 24: 323-33, 2001.
[Journal]
299)  Touloukian CE, Leitner WW, Robbins PF, Rosenberg SA, Restifo NP.
Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.
Cancer Res. 61: 8100-4, 2001.
[Journal]
300)  Chang E, Rosenberg SA.
Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy.
J Immunother. 24: 88-90, 2001.
[Journal]
301)  Rosenberg SA.
Progress in human tumour immunology and immunotherapy.
Nature. 411: 380-4, 2001.
[Journal]
302)  Rosenberg SA.
Progress in the development of immunotherapy for the treatment of patients with cancer.
J. Intern. Med. 250: 462-75, 2001.
[Journal]
303)  Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH, Nguyen DM, Rosenberg SA, Schrump DS.
Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.
J Immunother. 24: 151-61, 2001.
[Journal]
304)  Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch P, Riker AI, Kammula US, Rosenberg SA, Marincola FM.
Short-term kinetics of tumor antigen expression in response to vaccination.
J Immunol. 167: 1809-20, 2001.
[Journal]
305)  Liu K, Rosenberg SA.
Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity.
J Immunol. 167: 6356-65, 2001.
[Journal]
306)  Harada M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.
Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.
Cancer Res. 61: 1089-94, 2001.
[Journal]
307)  Panelli MC, Bettinotti MP, Lally K, Ohnmacht GA, Li Y, Robbins P, Riker A, Rosenberg SA, Marincola FM.
A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.
J Immunol. 164: 4382-92, 2000.
[Journal]
308)  Marroquin CE, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ.
Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer.
J Immunother. 23: 387-92, 2000.
[Journal]
309)  Parker LL, Do MT, Westwood JA, Wunderlich JR, Dudley ME, Rosenberg SA, Hwu P.
Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer.
Hum Gene Ther. 11: 2377-87, 2000.
[Journal]
310)  Panelli MC, Riker A, Kammula U, Wang E, Lee KH, Rosenberg SA, Marincola FM.
Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
J Immunol. 164: 495-504, 2000.
[Journal]
311)  Atkins MB, Kunkel L, Sznol M, Rosenberg SA.
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
Cancer J Sci Am. 6 Suppl 1: S11-4, 2000.
[Journal]
312)  Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Brenner M, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Boucher RC, Siegler HF, Barranger JA, Karlsson S, Kohn D, Galpin JE, Raffel C, Hesdorffer C, Ilan J, Cassileth P, O'Shaughnessy J, Kun LE, Das TK, Wong-Staal F, Sobol RE, Haubrich R, Sznol M, Rubin J, Sorcher EJ, Rosenblatt J, Walker R, Brigham K, Vogelzang N, Hersh E, Eck SL.
Human gene marker/therapy clinical protocols.
Hum Gene Ther. 11: 919-79, 2000.
[Journal]
313)  Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, Restifo NP.
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
J Immunol. 164: 3535-42, 2000.
[Journal]
314)  Rosenberg SA.
Identification of cancer antigens: impact on development of cancer immunotherapies.
Cancer J. 6 Suppl 3: S200-7, 2000.
[Journal]
315)  Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF.
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.
J Immunol. 165: 1153-9, 2000.
[Journal]
316)  Fritsch M, Rosenberg SA, Duray PH.
Immunohistologic responses within dermal metastatic melanoma lesions of patients treated with a synthetic peptide vaccine.
J Immunother. 23: 557-69, 2000.
[Journal]
317)  Lindsey KR, Rosenberg SA, Sherry RM.
Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
J Clin Oncol. 18: 1954-9, 2000.
[Journal]
318)  Rosenberg SA.
Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.
Cancer J Sci Am. 6 Suppl 1: S2-7, 2000.
[Journal]
319)  Stewart JH, Rosenberg SA.
Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine.
J Immunother. 23: 401-4, 2000.
[Journal]
320)  Fisher RI, Rosenberg SA, Fyfe G.
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.
Cancer J Sci Am. 6 Suppl 1: S55-7, 2000.
[Journal]
321)  Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA, Marincola FM.
Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
J Immunother. 23: 487-98, 2000.
[Journal]
322)  McKee MD, Clay TM, Diamond RA, Rosenberg SA, Nishimura MI.
Quantitation of T-cell receptor frequencies by competitive polymerase chain reaction: dynamics of T-cell clonotype frequencies in an expanding tumor-infiltrating lymphocyte culture.
J Immunother. 23: 419-29, 2000.
[Journal]
323)  Kammula US, Marincola FM, Rosenberg SA.
Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination.
J Natl Cancer Inst. 92: 1336-44, 2000.
[Journal]
324)  Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, Wunderlich JR, Yannelli JR, Rosenberg SA.
Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
J Immunother. 23: 17-27, 2000.
[Journal]
325)  Nielsen MB, Monsurro V, Migueles SA, Wang E, Perez-Diez A, Lee KH, Kammula U, Rosenberg SA, Marincola FM.
Status of activation of circulating vaccine-elicited CD8+ T cells.
J Immunol. 165: 2287-96, 2000.
[Journal]
326)  Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA.
T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Cancer J. 6: 69-77, 2000.
[Journal]
327)  Rosenberg SA.
The identification of cancer antigens: impact on the development of cancer vaccines.
Cancer J. 6 Suppl 2: S142-9, 2000.
[Journal]
328)  Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht GA, Steinberg SM, Rosenberg SA, Marincola FM.
Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes.
Int J Cancer. 86: 818-26, 2000.
[Journal]
329)  Ladányi A, Nishimura MI, Rosenberg SA, Yang JC.
Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide.
J Immunother. 23: 36-47, 2000.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 7/9/2014.